Wiley
Wiley.com
Print this page Share

Handbook of Contemporary Neuropharmacology, 3 Volume Set

David R. Sibley (Editor-in-Chief), Israel Hanin (Associate Editor), Michael Kuhar (Associate Editor), Phil Skolnick (Associate Editor)
ISBN: 978-0-471-66053-8
3040 pages
March 2007
Handbook of Contemporary Neuropharmacology, 3 Volume Set (0471660531) cover image
Written and edited by recognized experts, this comprehensive reference is also available online via Wiley InterScience.
  • Provides a readily accessible reference for students, professionals and libraries alike.
  • Editors are recognized authorities in the neuropharmacology and science field.
  • Comprehensive reference text for active junior and senior neurobiologists.
  • Fills an important niche as a text between research publications and clinical applications.

The Handbook of Contemporary Neuropharmacology is an invaluable resource for principal investigators and working scientists in academia, government and industry. This three volume set it also of interest for academic physicians, postdoctoral fellows and residents, and all high-level graduate students.

See More
Preface.

Contributors.

VOLUME 1.

PART I: BASIC NEUROPHARMACOLOGY.

Chapter 1: Soup or Sparks: The History of Drugs and Synapses (William Van der Kloot).

Chapter 2: Synaptic Transmission: Intercellular Signaling (J. David Jentsch and Robert H. Roth).

Chapter 3: Synaptic Transmission: Intracellular Signaling (R. Benjamin Free, Lisa A. Hazelwood, Yoon Namkung Michele L. Rankin, Elizabeth B. Rex, and David R. Sibley).

Chapter 4: Neuronal Nicotinic Receptors: One Hundred Years of Progress (Kenneth J. Kellar and Yingxian Xiao).

Chapter 5: Muscarinic Acetylcholine Receptors (Jürgen Wess).

Chapter 6: Norepinephrine/Epinephrine (Megan E. Kozisek and David B. Bylund).

Chapter 7: Dopaminergic Neurotransmission (John A. Schetz and David R. Sibley).

Chapter 8: Serotonin Systems (John A. Gray and Bryan L. Roth).

Chapter 9: Neuropharmacology of Histamine in Brain (Raphae¨l Faucard and Jean-Charles Schwartz).

Chapter 10: Ionotropic Glutamate Receptors (David Bleakman, Andrew Alt, David Lodge, Daniel T. Monaghan, David E. Jane, and Eric S. Nisenbaum).

Chapter 11: Metabotropic Glutamate Receptors (James A. Monn, Michael P. Johnson, and Darryle D. Schoepp).

Chapter 12: Pharmacology of the GABAA Receptor (Dmytro Berezhnoy, Maria C. Gravielle, and David H. Farb).

Chapter 13: Metabotropic GABA Receptors (Martin Gassmann and Bernhard Bettler).

Chapter 14: Voltage-Gated Ion Channels (Alex Fay, Patrick C. G. Haddick, and Lily Yeh Jan).

Chapter 15: Neuropeptides (Fleur L. Strand).

Chapter 16: Neurotransmitter Transporters (Jia Hu, Katherine Leitzell, Dan Wang, and Michael W. Quick).

Chapter 17: Gaseous Signaling: Nitric Oxide and Carbon Monoxide as Messenger Molecules (Kenny K. K. Chung, Valina L. Dawson, and Ted M. Dawson).

PART II: MOOD DISORDERS.

Chapter 18: Neurobiology and Treatment of Depression (Alexander Neumeister, Dennis S. Charney, Gerard Sanacora, and John H. Krystal).

Chapter 19: Neurotrophic Factors in Etiology and Treatment of Mood Disorders (Ronald S. Duman).

Chapter 20: Antidepressant Treatment and Hippocampal Neurogenesis: Monoamine and Stress Hypotheses of Depression Converge (Alex Dranovsky and René Hen).

Chapter 21: Neuroendocrine Abnormalities in Women with Depression Linked to the Reproductive Cycle (Barbara L. Parry, Charles J. Meliska, L. Fernando Martinez, Eva L. Maurer, Ana M. Lopez, and Diane L. Sorenson).

Chapter 22: Neurobiology and Pharmacotherapy of Bipolar Disorder (R. H. Belmaker, G. Agam, and R. H. Lenox).

Index.

Cumulative Index.

VOLUME 2.

PART I: ANXIETY AND STRESS DISORDERS.

Chapter 1: Neurobiology of Anxiety (Miklos Toth and Bojana Zupan).

Chapter 2: Pharmacotherapy of Anxiety (Jon R. Nash and David J. Nutt).

Chapter 3: Benzodiazepines (Hartmut Lu¨ddens and Esa R. Korpi).

Chapter 4: Neuroactive Steroids in Anxiety and Stress (Deborah A. Finn and Robert H. Purdy).

Chapter 5: Emerging Anxiolytics: Corticotropin-Releasing Factor Receptor Antagonists (Dimitri E. Grigoriadis and Samuel R. J. Hoare).

Chapter 6: Neurobiology and Pharmacotherapy of Obsessive-Compulsive Disorder (Judith L. Rapoport and Gale Inoff-Germain).

PART II: SCHIZOPHRENIA AND PSYCHOSIS.

Chapter 7: Phenomenology and Clinical Science of Schizophrenia (Subroto Ghose and Carol Tamminga).

Chapter 8: Dopamine and Glutamate Hypotheses of Schizophrenia (Bita Moghaddam and Houman Homayoun).

Chapter 9: Molecular Genetics of Schizophrenia (Liam Carroll, Michael C. O’Donovan, and Michael J. Owen).

Chapter 10: Postmortem Brain Studies: Focus on Susceptibility Genes in Schizophrenia (Shiny V. Mathew, Shruti N. Mitkus, Barbara K. Lipska, Thomas M. Hyde, and Joel E. Kleinman).

Chapter 11: Pharmacotherapy of Schizophrenia (Zafar Sharif, Seiya Miyamoto, and Jeffrey A. Lieberman).

Chapter 12: Atypical Antipsychotic Drugs: Mechanism of Action (Herbert Y. Meltzer).

PART III: SUBSTANCE ABUSE AND ADDICTIVE DISORDERS.

Chapter 13: Introduction to Addictive Disorders: Implications for Pharmacotherapies (Mary Jeanne Kreek).

Chapter 14: Dopaminergic and GABAergic Regulation of Alcohol-Motivated Behaviors: Novel Neuroanatomical Substrates (Harry L. June and William J. A. Eiler II).

Chapter 15: Nicotine (August R. Buchhalter, Reginald V. Fant, and Jack E. Henningfield).

Chapter 16: Psychostimulants (Leonard L. Howell and Heather L. Kimmel).

Chapter 17: MDMA and Other "Club Drugs" (M. Isabel Colado, Esther O’Shea, and A. Richard Green).

Chapter 18: Marijuana: Pharmacology and Interaction with the Endocannabinoid System (Jenny L. Wiley and Billy R. Martin).

Chapter 19: Opiates and Addiction (Frank J. Vocci).

PART IV: PAIN.

Chapter 20: Neuronal Pathways for Pain Processing (Gavril W. Pasternak and Yahong Zhang).

Chapter 21: Vanilloid Receptor Pathways (Makoto Tominaga).

Chapter 22: Opioid Receptors (Gavril W. Pasternak).

Chapter 23: Advent of A New Generation of Antimigraine Medications (Ana Recober and Andrew F. Russo).

Index.

Cumulative Index.

VOLUME 3.

PART I: SLEEP AND AROUSAL.

Chapter 1: Function and Pharmacology of Circadian Clocks (Gabriella B. Lundkvist and Gene D. Block).

Chapter 2: Melatonin Receptors in Central Nervous System (Margarita L. Dubocovich).

Chapter 3: Narcolepsy: Neuropharmacological Aspects (Seiji Nishino).

Chapter 4: Hypocretin/Orexin System (J. Gregor Sutcliffe and Luis de Lecea).

Chapter 5: Prokineticins: New Pair of Regulatory Peptides (Michelle Y. Cheng and Qun-Yong Zhou).

Chapter 6: Sedatives and Hypnotics (Keith A. Wafford and Paul J. Whiting).

PART II: DEVELOPMENT AND DEVELOPMENTAL DISORDERS.

Chapter 7: Regulation of Adult Neurogenesis (Heather A. Cameron).

Chapter 8: Neurotrophic Factors (Franz F. Hefti and Patricia A. Walicke).

Chapter 9: Neurotrophins and Their Receptors (Mark Bothwell).

Chapter 10: Tourette’s Syndrome and Pharmacotherapy (Pieter Joost van Wattum and James F. Leckman).

Chapter 11: Neuropharmacology of Attention-Deficit/Hyperactivity Disorder (Paul E. A. Glaser, F. Xavier Castellanos, and Daniel S. Margulies).

Chapter 12: Psychopharmacology of Autism Spectrum Disorders (Adriana Di Martino, Steven G. Dickstein, Alessandro Zuddas, and F. Xavier Castellanos).

PART III: NEURODEGENERATIVE AND SEIZURE DISORDERS.

Chapter 13: Stroke: Mechanisms of Excitotoxicity and Approaches for Therapy (Michael J. O’Neill, David Lodge, and James McCulloch).

Chapter 14: Epilepsy: Mechanisms of Drug Action and Clinical Treatment (William H. Theodore and Michael A. Rogawski).

Chapter 15: Pharmacotherapy for Traumatic Brain Injury (Donald G. Stein and Stuart W. Hoffman).

Chapter 16: Dementia and Pharmacotherapy: Memory Drugs (Jerry J. Buccafusco).

Chapter 17: Pharmacotherapy and Treatment of Parkinson’s Disease (Wing Lok Au and Donald B. Calne).

Chapter 18: Parkinson’s Disease: Genetics and Pathogenesis (Claudia M. Testa).

Chapter 19: Invertebrates as Powerful Genetic Models for Human Neurodegenerative Diseases (Richard Nass and Charles D. Nichols).

PART IV: NEUROIMMUNOLOGY.

Chapter 20: Myelin Lipids and Proteins: Structure, Function, and Roles in Neurological Disorders (Richard H. Quarles).

Chapter 21: Pharmacology of Inflammation (Carmen Espejo and Roland Martin).

Chapter 22: Pharmacological Treatment of Multiple Sclerosis (B. Mark Keegan).

Chapter 23: Novel Therapies for Multiple Sclerosis (Martin S. Weber and Scott S. Zamvil).

Chapter 24: Neuropharmacology of HIV/AIDS (Sidney A. Houff and Eugene O. Major).

PART V: EATING AND METABOLIC DISORDERS.

Chapter 25: Leptin: A Metabolic Perspective (Dawn M. Penn, Cherie R. Rooks, and Ruth B. S. Harris).

Chapter 26: Ghrelin: Structural and Functional Properties (Birgitte Holst, Kristoffer Egerod, and Thue W. Schwartz).

Chapter 27: Mechanisms Controlling Adipose Tissue Metabolism by the Sympathetic Nervous System: Anatomical and Molecular Aspects (Sheila Collins, Renato H. Migliorini, and Timothy J. Bartness).

Chapter 28: Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives (Yuguang Shi).

Index.

Cumulative Index.

See More
DAVID R. SIBLEY, PhD, is a Senior Investigator and Chief of the Molecular Neuropharmacology Section in the National Institute of Neurological Disorders and Stroke, National Institutes of Health. His laboratory is currently investigating the molecular, cellular, and biochemical properties of dopamine receptors and their role in neuronal signaling and pathophysiological states.

ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin's research has focused on cholinergic mechanisms, animal models for Alzheimer's disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer's disease.

MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.

PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.

See More
"...an admirable job of bringing together many aspects of neuropharmacology in one place...well worth your while to examine it." (Journal of Medicinal Chemistry, September 20, 2007)
See More

Related Titles

Back to Top